Fruehauf and colleagues (2007) discussed the combination of mitoxanthrone and etoposide to treat a blast crisis
Soupir et al3 performed a multi-institutional retrospective analysis of cases of Ph+ AMLs and CML in blast crisis
and showed that Ph+ AMLs differed from CML in blast crisis
by different clinical pictures (no splenomegaly nor basophilia in Ph+ AML), bone marrow morphology (lower cellularity and myeloid to erythroid ratio in Ph+ AML), cytogenetic findings (characteristic other chromosomal abnormalities usually found in CML were not seen in Ph+ AML), and response to chemotherapy (return to normal karyotype was observed in cases of Ph+ AML, whereas persistence of Ph+ was seen in CML); however, the median survival was similar between the 2 groups.
Our findings also suggest that maintaining the level of this microRNA might represent a new therapeutic strategy for CML blast crisis
patients who do not benefit from targeted agents such as imatinib (Gleevec) and dasatinib (Sprycel)," Perrotti added.
CML progresses through three distinct phases: the chronic phase (typically lasting from four to five years), the accelerated phase (typically lasting from six to 18 months) and blast crisis
(typically lasting from three to six months).
Approximately 3 years after the diagnosis of chronic phase CML, metamorphosis through periods of accelerated growth and blast crisis
Combinations of chemotherapeutic drugs or autologous bone marrow transplantation can also be used for the lymphoid or myeloid blast crisis
, but this therapy is more effective if given in the chronic phase of the disease.
It is typically slow-growing and often not diagnosed until its later stages when there can be a sudden, dramatic increase in malignant cells, known as blast crisis
Tasigna produced deeper levels of molecular response than Glivec in front-line Ph+ CML and significantly reduced progression to accelerated phase and blast crisis
, resulting in fewer deaths due to CML.
Toluidine blue (TB) is a basic dye that helps in identification of myeloid blasts showing differentiation towards basophils, which may be seen in acute basophilic leukemia, basophilic blast crisis
of chronic myeloid leukemia (CML) and AML with basophilia.
4% of those on imatinib progressed to the accelerated phase or blast crisis
of the disease, said lead investigator Dr.